CSL Limited (CSL.AX)
| Previous close | 283.55 |
| Open | 285.90 |
| Bid | 285.40 x 0 |
| Ask | 285.50 x 0 |
| Day's range | 283.98 - 286.49 |
| 52-week range | 254.30 - 314.28 |
| Volume | |
| Avg. volume | 752,939 |
| Market cap | 137.673B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 37.69 |
| EPS (TTM) | 7.57 |
| Earnings date | 14 Feb 2023 |
| Forward dividend & yield | 3.18 (1.04%) |
| Ex-dividend date | 06 Sept 2022 |
| 1y target est | 326.44 |
- PR Newswire
Tavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that Tavneos® has been included in the revised EULAR AAV management recommendations, as one of several important updates in the 2022 version. As part of a strategy to substantially reduce exposure to glucocorticoids, Tavneos® should be considered a therapy option in combination with rituximab or cyclophosphamide for induction of remission in patients with active granulomatosis with polyangiitis (GPA) or microscopic polyang
- PR Newswire
CSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts
Global biotechnology leader CSL (ASX: CSL; USOTC:CSLLY) today celebrated the official opening of the company's new state-of-the-art research and development (R&D) center in Waltham, Massachusetts. The custom-built facility is approximately 140,000 square feet with 54,000 square feet of lab space, including the first biosafety level 3 laboratory (BSL-3) in Waltham. The site will serve as CSL's central hub for current and future vaccine design.
- PR Newswire
The Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE
Global biotechnology leader CSL (ASX:CSL;USOTC:CSLLY), announced that The Lancet has published results from the Phase 3 VANGUARD study evaluating garadacimab (CSL312) as a once-monthly, prophylactic treatment for attacks due to hereditary angioedema (HAE). The Lancet paper provides detailed data on the Phase 3 study, which were recently presented during the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. The study met its primary and secondary
